



celares GmbH establishes collaboration with NOF

Berlin, 07 November 2012

The Berlin drug delivery company, celares GmbH, has established a marketing collaboration with NOF CORPORATION (Japan). NOF is a worldwide leader in the supply of polymer based drug delivery reagents and celares is a well-known specialist for the delivery of biologics by chemical modification and PEGylation.

PEGylation is a recognized delivery system for biologics such as peptides, proteins, antibody fragments, and oligonucleotide aptamers. PEGylation can significantly improve pharmacological and physicochemical properties with half-life extension being the main benefit.

NOF CORPORATION, Japan, and celares GmbH, Germany, have now established strategic collaboration in the field of PEGylation. The collaboration will enable NOF CORPORATION to strengthen its leading position in an increasingly competitive market for Activated PEG supply. Collaboration of celares with NOF means a milestone in company development. In joint client projects, celares will use NOF's high grade pure Activated PEGs. For celares, the collaboration with NOF means a broadening of its market globally.

Clients will benefit from the combined comprehensive know-how of NOF and celares in PEG-related developments. NOF provides highly pure Activated PEGs from R&D to market scale. celares provides know-how in the successful development of PEGylated proteins and peptides.

***NOF CORPORATION** is market leader in the supply of activated polyethylene glycol (PEG) derivatives (Activated PEGs) with molecular weights ranging from 2kDa to 80kDa. The company has over 20 years of experience in supplying high-quality methoxy polyethylene glycol (mPEGs) for pharmaceutical applications which are patented through the proprietary SUNBRIGHT® technology. These Activated PEGs are characterized by a narrow polydispersity and extremely low impurity profile.*

***celares GmbH** is a specialist for the delivery of biologics by chemical modification and PEGylation. The company provides customized services including feasibility studies, development of reaction conditions and purification process, as well as development and validation of analytical methods. Furthermore, celares produces pilot batches of PEGylated or chemically modified biologics for animal studies and performs stability studies according to ICH guidelines.*

Contact

celares GmbH

Dr. Frank Leenders

Gebäude D80

Robert-Roessle-Straße 10

D-13125 Berlin

Germany

Internet: www.celares.com

Mail: info@celares.com

Telefon: +49-30-9489-2354

Fax: +49-30-9489-2351